病例对照疫苗效果研究:准备、设计及病例与对照的入组
病例对照研究常用于评估已上市疫苗在公共卫生项目中的效果,可提供真实世界条件下疫苗性能的政策相关数据。2012年专家组会议总结了病例对照疫苗效果研究在规划、设计和病例与对照入组方面的最佳实践建议。研究应重点理解医疗寻求和疫苗接种实践等背景,疫苗上市后尽早开展,使用疫苗特异性终点,对照应代表源人群,匹配仅限关键变量。
要点
- 病例对照疫苗效果研究可提供真实世界疫苗性能数据,但存在偏倚和混杂,可能误导政策决策。
- 严格规划准备应聚焦理解研究背景,包括医疗寻求和疫苗接种实践。
- 疫苗上市后尽早开展研究,因高覆盖率易产生强混杂;终点应疫苗特异性而非非特异性临床综合征。
核心结论
- 病例对照疫苗效果研究可为政策决策和疫苗开发提供有用信息,但严格的准备和设计至关重要。
研究设计与样本
- 2012年专家组开会回顾近期评估多种疫苗效果的病例对照研究经验,总结关于规划、设计和病例与对照入组的最佳实践建议。
主要发现
- 病例对照研究不测量疫苗上市对人群层面疾病的影响,且易受偏倚和混杂影响,可能导致不准确结果而误导政策决策。
- 严格规划准备应聚焦理解研究背景,包括医疗寻求和疫苗接种实践。
- 病例对照疫苗效果研究最好在疫苗上市后尽早开展,因高覆盖率产生强混杂的潜力大。
- 疫苗特异性终点优于非特异性临床综合征,因非特异性结局中可通过接种预防的比例可能随时间和地点变化,导致结果可能令人困惑。
- 对照应代表病例来源的源人群,一般从社区或病例入组的卫生机构招募;匹配常用于潜在混杂因素,但应仅限与接种和疾病均相关的少数关键变量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 病例对照研究不测量疫苗上市对人群层面疾病的影响。
- 病例对照研究易受偏倚和混杂影响,可能导致不准确结果而误导政策决策。
- 非特异性结局中可通过接种预防的比例可能随时间和地点变化,导致结果可能令人困惑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Case-control studies are commonly used to evaluate effectiveness of licensed vaccines after deployment in public health programs. Such studies can provide policy-relevant data on vaccine performance under 'real world' conditions, contributing to the evidence base to support and sustain introduction of new vaccines. However, case-control studies do not measure the impact of vaccine introduction on disease at a population level, and are subject to bias and confounding, which may lead to inaccurate results that can misinform policy decisions. In 2012, a group of experts met to review recent experience with case-control studies evaluating the effectiveness of several vaccines; here we summarize the recommendations of that group regarding best practices for planning, design and enrollment of cases and controls. Rigorous planning and preparation should focus on understanding the study context including healthcare-seeking and vaccination practices. Case-control vaccine effectiveness studies are best carried out soon after vaccine introduction because high coverage creates strong potential for confounding. Endpoints specific to the vaccine target are preferable to non-specific clinical syndromes since the proportion of non-specific outcomes preventable through vaccination may vary over time and place, leading to potentially confusing results. Controls should be representative of the source population from which cases arise, and are generally recruited from the community or health facilities where cases are enrolled. Matching of controls to cases for potential confounding factors is commonly used, although should be reserved for a limited number of key variables believed to be linked to both vaccination and disease. Case-control vaccine effectiveness studies can provide information useful to guide policy decisions and vaccine development, however rigorous preparation and design is essential.
引用
- Verani JR, Baqui AH, Broome CV, et al. Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine. 2017. PMID: 28442231. doi:10.1016/j.vaccine.2017.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。